The filing for a mixed shelf offering by NeuroBo Pharmaceuticals indicates a strategic move to secure funding for future projects or operational needs. This could be viewed positively by investors as it provides the company with financial flexibility and the ability to capitalize on market conditions to fund growth initiatives. However, the impact on the stock price will depend on investor perception of the company's growth prospects and how effectively it plans to use the raised capital.